Selected practical aspects of intermittent hemodialysis in acute renal failure patients

Contributions to Nephrology

Volumn 132, Issue , 2001, Pages 222-235

  Dhondt, Annemieke ^a   Van Biesen, Wim ^a   Vanholder, Raymond ^a   Lameire, Norbert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ACUTE KIDNEY FAILURE; HEMOFILTRATION; HUMAN; INSTRUMENTATION; RENAL REPLACEMENT THERAPY; REVIEW; TIME; ULTRAFILTRATION;

ANTICOAGULANTS; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; RENAL DIALYSIS; TIME FACTORS; ULTRAFILTRATION;

EID: 0035532675     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060090     Document Type: Article

References (58)

1. Lameire N, Van Biesen W, Vanholder R, Colardyn F: The place of intermittent hemodialysis in the treatment of acute renal failure in the ICU patient. Kidney Int 1998;53(suppl 66):S110-S119.
2. Turney J, Marshall D, Brownjohn A, Ellis C, Parsons F: The evolution of acute renal failure 1956-1988. Q J Med 1990;74:83-104.
3. McCarthy J: Prognosis of patients with acute renal failure in the intensive care unit: A tale of two eras. Mayo Clin Proc 1996;71:117-126.
4. Paganini E: Continuous renal replacement therapy: A nephrological technique, managed by nephrology. Semin Dial 1996;9:200-203.
5. Fassbinder W: Renaissance of the batch method? Nephrol Dial Transplant 1998;13:3010-3012.
6. Lonnemann G, Floege J, Kliem V, Brunkhorst R, Koch K: Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single patch batch dialysis system. Nephrol Dial Transplant 2000;- 15:1189-1193.
7. Arnaout M, Hakim R, Todd R, Dana N, Colten H: Increased expresson of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985;312:457-462.
8. Hörl W, Schaeffer R, Heidland A: Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol 1985;5:320-326.
9. Nguyen A, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B: Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int 1985;28:158-167.
10. Himmelfarb J, Lazarus M, Hakim R: Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991;3:271-276.
11. Descamps-Latscha B, Goldfarb B, Nguyen A, Landais P, London G, Haeffner-Cavaillon N, Jacquot C, Herbelin A, Kazatchkine M: Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialysis patients: A randomized prospective study. Nephron 1991;59:279-285.
12. Hartmann J, Fricke H, Schiffl H: Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997;30:366-373.
13. McCarthy J, Jenson B, Squillace D, Williams A: Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997;29:576-583.
14. Vanholder R, De Vriese A, Lameire N: The role of dialyzer biocompatibility in acute renal failure. Blood Purif 2000;18:1-12.
15. Schiffl H: Biocompatibility and acute renal failure (letter). Lancet 2000;355;312.
16. Schiffl H, Lang S, König A, Strasser T, Haider M, Held E: Biocompatible membranes in acute renal failure: Prospective case-controlled study. Lancet 1994;344:570-572.
17. Hörl W, Schäfer R, Hörl M, Heidland A: Neutrophil activation in acute renal failure and sepsis. Arch Surg 1990;125:651-654.
18. Vanholder R, Lameire N: Does biocompatibility of dialysis membranes affect recovery of renal function and survival? Lancet 1999;354:1316-1318.
19. Hakim R, Wingard R, Parker R: Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994;331:1338-1342.
20. Splendiani G, Mazzarella V: Is the choice of membrane important for patients with acute renal failure requiring hemodialysis (letter). Artif Organs 1996;20:281.
21. Schiffl H, Sitter T, Lang S, König A, Haider M, Held E: Bioincompatible membranes place patients with acute renal failure at increased risk for infection. ASAIO J 1995;41:M709-M712.
22. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P, the French Study Group on Acute Renal Failure: Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. Nephrol Dial Transplant 1996;11:293-299.
23. Mehta R, MacDonald B, Gabbai F, Pahl M, Farkas A, Pascual M, Fowler W: Effect of biocompatible membranes on outcomes from acute renal failure in the ICU (abstract). J Am Soc Nephrol 1996;7:1457.
24. Himmelfarb J, Tolkoff-Rubin N, Chandran P, Parker R, Wingard R, Hakim R: A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998;9:257-266.
25. Gastadello K, Melot C, Kahn R, Vanherweghem J, Vincent J, Tielemans C: Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized trial. Nephrol Dial Transplant 2000;15:224-230.
26. Assouad M, Tseng S, Dunn K, Gonzales J, Brennan S, Suki W: Biocompatibility of dialyzer membrane is important in the outcome of acute renal failure (abstract). J Am Soc Nephrol 1996;7:1447.
27. Albright R, Smelser J, McCarthy J, Bergstrahl E, Larson T: Patient survival and renal recovery in acute renal failure: Comparison of cellulose acetate vs. polysulfone dialysis membranes (abstract). J Am Soc Nephrol 1998;9:197.
28. Liano F, Pascual J, the Madrid Acute Renal Failure Study Group: Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Kidney Int 1996;50:811-818.
29. Jörres A, Gahl G, Dobis C, Polenakovic M, Cakalaroski K, Rutkowski B, Kisielnicka E, Krieter D, Rumpf W, Guenther C, Gaus W, Hoegel J and the Multicentre Group: Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: A prospective randomized multicentre trial. Lancet 1999;354:1337-1341.
30. Cimochowski G, Worley E, Rutherford W, Sartain J, Blondin J, Harter H: Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990;54:154-161.
31. Vanholder R, Hoenich N, Ringoir S: Dialysis performance of single lumen subclavian hemodialysis: A comparative study with single lumen fistula hemodialysis. Artif Organs 1982;6:429-432.
32. Vanholder R, Ringoir S: Vascular access for hemodialysis. Artif Organs 1994;18:263-265.
33. Van Wetering J, Westendorp R, Van Der Hoeven J, Feuth J, Chang P: Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
34. Davenport A: Problems with anticoagulation for continuous renal replacement therapies; in Lameire N, Metha R (eds): Complications of Dialysis. New York, Dekker, 2000, pp 215-240.
35. Pinnick R, Wiegmann T, Diederich D: Regional citrate anticoagulation for hemodialysis in the patient with high risk for bleeding. N Engl J Med 1983;308:258-261.
36. Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl W: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996;7:234-241.
37. Dhondt A, Vanholder R, Waterloos M, Glorieux G, De Smet R, Lameire N: Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. Nephrol Dial Transplant 1998;13:1752-1758.
38. Janssen M, Deegens J, Kapinga T, Beukhof J, Huijgens P, Van Loenen A, Van Der Meulen J: Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996;49:806-813.
39. Seaton R, Duncan K, Pinnick R, Diederich D, Wiegmann T: Regional citrate anticoagulation in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 1983;29:414-418.
40. Wiegmann T, MacDougall M, Diederich D: Dialysis leukopenia, hypoxemia and anaphylatoxin formation: Effect of memebrane, bath, and citrate anticoagulation. Am J Kidney Dis 1988;11:418-424.
41. Hocken A, Hurst P: Citrate regional anticoagulation in hemodialysis. Nephron 1987;46:7-10.
42. Von Brecht J, Flanigan M, Freeman R, Lim V: Regional anticoagulation: Hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986;8:196-201.
43. Collart F, Wens R, Dratwa M: Regional anticoagulation with sodium citrate: Chronic utilization in the hemodialysis patient. Nephrologie 1993;14:151-154.
44. Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, Lamaire F, Brochard L: Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: Usefulness of practice guidelines. Am J Respir Crit Care Med 2000;162:197-202.
45. Paganini E, Tapolyai M, Goormastic M, Halstenberg W, Kozlowski L, Leblanc M, Lee J, Moreno L, Sakai K: Establishing a dialysis therapy/patient outcome link in intensive care unit acute dialysis for patients with acute renal failure. Am J Kidney Dis 1996;28(suppl 3):S81-S89.
46. Ronco C, Bellomo R, Hommel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous veno-veneus haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 2000;355:26-30.
47. Himmelfarb J, Ikizler T: Quantitating urea removal in patients with acute renal failure: Lost art or forgotten science? Semin Dial 2000;13:147-149.
48. Evanson J, Ikizler T, Wingard R, Knights S, Shyr Y, Schulman G, Himmelfarb J, Hakim R: Measurement of the delivery of dialysis in acute renal failure. Kidney Int 1999;55:1501-1508.
49. Schiffl H, Lang S, Konig A, Held E: Dose of intermittent hemodialysis and outcome of acute renal failure: A prospective randomized study (abstract). J Am Soc Nephrol 1997;8:291.
50. Keshaviah P: The solute removal index: A unified basis for comparing disparate therapies. Peril Dial Int 1995;15:101-104.
51. Depner T: Benefits of more frequent dialysis: Lower TAC at the same Kt/V. Nephrol Dial Transplant 1998;13(suppl 6):20-24.
52. Evanson J, Himmelfarb J, Wingard R, Knights S, Shyr Y, Schulman G, Ikizler T, Hakim R: Prescribed versus delivered dialysis in acute renal failure patients. Am J Kidney Dis 1998;32:731-738.
53. Clark W, Mueller B, Kraus M, Macias W: Extracorporeal therapy requirements for patients with acute renal failure. J Am Soc Nephrol 1997;8:804-812.
54. Frankenfield D, Reynolds H, Wiles C, Badellino M, Siegel J: Urea removal during continuous hemodiafiltration. Crit Care Med 1994;22:407-421.
55. Paganini E, Sandy D, Moreno L, Kozlowski L, Sakai K: The effect of sodium and ultrafiltration modeling on plasma volume changes and haemodynamic stability in intensive care patients receiving haemodialysis for acute renal failure: A prospective, stratified, randomized, cross-over study. Nephrol Dial Transplant 1996;11(suppl 8):32-37.
56. Van Der Sande F, Gladziwa U, Kooman J, Böcker G, Leunissen K: Energy transfer is the single most important factor for the difference in vascular response between isolated ultrafiltration and hemodialysis. J Am Soc Nephrol 2000;11:1512-1517.
57. Grootendorst A, Van Bommel E, Van Der Hoven B, Van Leengoed L, Van Osta A: High volume hemofiltration improves right ventricular function of endotoxin induced shock in the pig. Intensive Care Med 1992;18:235-240.
58. De Vriese A, Colardyn F, Philippe J, Vanholder R, De Sutter J, Lameire N: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-853.